Superpower peptides available for pre-order. Get first access.

Peptide science

What is the history of GLP-1?

GLP-1 was found as a human hormone in the 1980s. A Gila monster venom peptide became the first GLP-1 drug in 2005, and weight-loss approvals followed.

Quick answer

GLP-1 was identified as a human hormone in the 1980s, with the first human study in 1987 showing it raised insulin in seven volunteers. Exenatide (Byetta), a synthetic copy of a Gila monster venom peptide, became the first GLP-1 drug in 2005. Liraglutide (Saxenda) brought the first weight-management approval in December 2014, and orforglipron (Foundayo), a non-peptide pill, gained a weight-management approval on April 1, 2026.

Published
November 9, 2026
Last updated
November 9, 2026

The history of GLP-1 from hormone to medicine

GLP-1 is a human gut hormone that researchers identified in the 1980s. The history of GLP-1 as a medicine starts with exenatide (Byetta), a synthetic copy of a Gila monster venom peptide. Exenatide became the first GLP-1 receptor agonist approved in 20051. GLP-1 drugs then spent nearly a decade in type 2 diabetes care before the first weight-management approval in 20142.

Every one of those drugs traces back to the lab work that first found GLP-1 in people.

Researchers identified GLP-1 as a human hormone in the 1980s

Researchers identified GLP-1 in the 1980s, first as a stretch of the proglucagon gene and then as a working hormone in people. The human proglucagon gene was characterized in 19833. In a 1987 human study4, GLP-1 infusion in seven volunteers raised insulin and lowered blood glucose. The finding placed GLP-1 among the incretins, gut hormones that boost insulin release after eating. GIP was the first incretin characterized, in the 1970s5.

GLP-1's discovery spanned several laboratories. Joel Habener's lab decoded anglerfish proglucagon in the early 1980s1. Graeme Bell and others identified the human sequence3. Svetlana Mojsov, also in Habener's lab, identified the shortened forms of GLP-11 that act in the body. In 1987, shortened GLP-1 potently stimulated insulin release in perfused rat pancreas6.

By 1992, researchers had shown that GLP-1 is released in people after a mixed meal and stimulates insulin more potently than GIP. GLP-1 fulfilled the classic criteria for a hormone7 and was described as likely to be a new incretin. GLP-1's insulin effect held up in type 2 diabetes, unlike GIP's5, so researchers set out to build a GLP-1 drug.

A Gila monster venom peptide became the first GLP-1 drug

The first GLP-1 drug came from exendin-4, a 39-amino-acid peptide in Gila monster venom8. Researchers isolated exendin-4 from the lizard's venom in 1992. A synthetic version of that peptide, exenatide, became the first approved GLP-1 drug.

GLP-1 itself is a human hormone, not a lizard product. Exendin-4 is a separate lizard peptide that activates the GLP-1 receptor with high potency9 in insulin-secreting cells and rat islets. Exendin-4 also shares 53% structural homology with human GLP-110.

Exendin-4 outlasts native GLP-1 because a glycine in its second position11 resists DPP-4, the enzyme that breaks GLP-1 down. The FDA approved exenatide as Byetta in 200512 for type 2 diabetes. Weight loss in people taking GLP-1 drugs for diabetes later pointed to a second use.

The history of GLP-1 drugs from diabetes to weight loss

The first GLP-1 drug approved for weight loss was liraglutide, in December 2014. The FDA approved liraglutide as Saxenda for chronic weight management in adults2. Weight loss seen with liraglutide in diabetes care led to its higher-dose approval for obesity13.

Semaglutide and tirzepatide followed liraglutide into weight management, each first approved for type 2 diabetes. Tirzepatide added a second target by activating both GIP and GLP-1 receptors14.

GLP-1 drugs also moved from injections to pills. Semaglutide tablets became the first oral GLP-1 receptor agonist15. The tablets pair the peptide with SNAC, an absorption enhancer that protects semaglutide in the stomach. Orforglipron (Foundayo) took a different route as a non-peptide small molecule taken by mouth16.

YearDrug (brand)US approved use
2005Exenatide (Byetta)Type 2 diabetes12
2010Liraglutide (Victoza)Type 2 diabetes17
2014Dulaglutide (Trulicity)Type 2 diabetes18
2014Liraglutide (Saxenda)Chronic weight management2
2017Semaglutide injection (Ozempic)Type 2 diabetes19
2019Semaglutide tablets (Rybelsus)Type 2 diabetes20
2021Semaglutide injection (Wegovy)Chronic weight management21
2022Tirzepatide (Mounjaro)Type 2 diabetes22
2023Tirzepatide (Zepbound)Chronic weight management14
2024Semaglutide injection (Wegovy)Lowering heart attack, stroke, and cardiovascular death risk23 in adults with cardiovascular disease and obesity or overweight
2025Semaglutide tablets (Wegovy)Weight reduction24 in adults with obesity, or overweight with a weight-related condition
2026Orforglipron (Foundayo)Weight reduction and maintenance25 in adults with obesity, or overweight with a weight-related condition

Each of these drugs began with the same obstacle, native GLP-1's short life in the bloodstream.

Why GLP-1 drugs took decades to engineer

GLP-1 drugs took decades to engineer because the enzyme DPP-4 breaks native GLP-1 down within minutes. In people with diabetes, GLP-1's circulating half-life is 1.5 to 2 minutes1.

Early analogues that resisted DPP-4 and stayed biologically active26 held up longer in lab tests and in anesthetized pigs. Later designs attached fatty acids that bind reversibly to the blood protein albumin13. Semaglutide used that albumin binding to reach a once-weekly design27. The same choices still shape how today's GLP-1 receptor agonists are built. GLP-1's short half-life is the problem every GLP-1 drug since Byetta was designed to get around.

Where can I learn about peptides?

The GLP-1 story runs from a 1980s gene discovery to weight-loss pills, and keeping its dates straight takes care. Superpower’s peptide library sets those milestones out in order, drawing on a team of health journalists and licensed clinicians who write and fact-check its content.

Readers curious about the chemistry that made long-acting GLP-1 drugs possible can explore the science behind peptides.

IMPORTANT SAFETY INFORMATION

GLP-1 receptor agonists are prescription medications approved by the FDA for specific indications. Whether any prescription therapy is appropriate is determined by a licensed healthcare provider. Compounded GLP-1 formulations are not FDA-approved28 and have not been evaluated by the FDA for safety, effectiveness, or quality; they are subject to current 503A compounding restrictions28 under FDCA § 353a29, and are dispensed only pursuant to a patient-specific prescription when a provider determines clinical appropriateness. This article is for educational purposes and is not a promotion of any specific medication or treatment.

Most GLP-1 receptor agonists carry a contraindication in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); this contraindication is agent-specific, so check the individual product's prescribing information. GLP-1 receptor agonists should not be used during pregnancy or breastfeeding. Pancreatitis has been reported; use with caution in individuals with a history of pancreatitis.

Common side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. Serious adverse events reported with this class include pancreatitis, gallbladder disease, and gastrointestinal obstruction30.

GLP-1 receptor agonists are prescription-only medications. This article does not constitute medical advice or prescribing guidance. Consult a qualified healthcare provider for evaluation and prescribing decisions. FDA-approved labeling31 sets out the complete indications, contraindications, and warnings for each approved agent.

More peptide science